Want to see IN:TAKE full AI Analyst Report?
TAKE Stock Chart & Stats
₹20.76
₹0.05(0.24%)
At close: 4:00 PM EDT
₹20.76
₹0.05(0.24%)
Day’s Range― - ―
52-Week Range₹10.95 - ₹49.90
Previous CloseN/A
Volume250.59K
Average Volume (3M)127.69K
Market Cap
₹1.78B
Enterprise Value₹5.86B
Total Cash (Recent Filing)₹2.80M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)14.5
Beta1.33
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.03%
Share Statistics
EPS (TTM)0.87
Shares Outstanding147,934,000
10 Day Avg. Volume111,180
30 Day Avg. Volume127,685
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)18.74
Price to Sales (P/S)10.72
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Life-sciences SpecializationA focused position in regulated life sciences gives TAKE a durable domain orientation and aligns its technology services with complex clinical, regulatory, quality, and commercial processes. This specialization can support relevance with clients over multiple quarters as those workflows remain essential to industry operations.
Debt-free Balance SheetZero reported debt materially reduces leverage-related financial risk and avoids the interest burden associated with borrowing. This provides greater flexibility to manage volatility, preserve available resources, and support operations without the refinancing pressure that affected the company in earlier periods.
Equity RecoveryThe return to positive stockholders’ equity represents a meaningful improvement from the FY2024 impairment and strengthens the company’s balance-sheet position. Although the recovery does not eliminate past volatility, it provides a more stable financial base for continuing operations over the coming quarters.
Bears Say
Negative Core ProfitabilityNegative gross and operating profit indicate that reported earnings are not currently being generated by the core business. Positive net income appears to depend on below-the-line items, weakening earnings quality and making near-term profitability less dependable until operating economics improve.
Weak Cash ConversionSustained negative operating cash flow alongside positive net income signals poor conversion of reported earnings into cash. This can restrict internally funded investment and working capital capacity, while increasing the importance of improving collections, operating margins, or other cash-generating activities.
Highly Volatile Financial RecordThe sharp revenue swings and repeated losses demonstrate an unstable earnings base rather than consistent growth. Such volatility makes business planning and resource allocation more difficult and leaves future performance sensitive to whether the latest revenue rebound can be sustained.
TAKE Solutions Limited News
TAKE FAQ
What was TAKE Solutions Limited’s price range in the past 12 months?
TAKE Solutions Limited lowest stock price was ₹10.95 and its highest was ₹49.90 in the past 12 months.
What is TAKE Solutions Limited’s market cap?
TAKE Solutions Limited’s market cap is ₹1.78B.
When is TAKE Solutions Limited’s upcoming earnings report date?
TAKE Solutions Limited’s upcoming earnings report date is Nov 14, 2026 which is in 25 days.
How were TAKE Solutions Limited’s earnings last quarter?
TAKE Solutions Limited released its earnings results on Aug 11, 2026. The company reported ₹0.072 earnings per share for the quarter.
Is TAKE Solutions Limited overvalued?
According to Wall Street analysts TAKE Solutions Limited’s price is currently Overvalued.
Does TAKE Solutions Limited pay dividends?
TAKE Solutions Limited pays a Semiannually dividend of ₹0.4 which represents an annual dividend yield of 1.03%. See more information on TAKE Solutions Limited dividends here
What is TAKE Solutions Limited’s EPS estimate?
TAKE Solutions Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TAKE Solutions Limited have?
TAKE Solutions Limited has 147,934,000 shares outstanding.
What happened to TAKE Solutions Limited’s price movement after its last earnings report?
TAKE Solutions Limited reported an EPS of ₹0.072 in its last earnings report. Following the earnings report the stock price went up 1.174%.
Which hedge fund is a major shareholder of TAKE Solutions Limited?
Currently, no hedge funds are holding shares in IN:TAKE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TAKE Solutions Limited
TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, the company delivers technology-driven and proprietary solutions, alongside consulting and practical services covering clinical trials, regulatory compliance, and patient safety. Its specific offerings in this area include clinical research, development of generic drugs, data analytics, regulatory affairs management, and pharmacovigilance. Beyond this, TAKE Solutions also offers IT infrastructure and support, comprehensive supply chain management, engineering, design, and sourcing services. The company caters to a diverse client base, encompassing both major and smaller innovative biopharmaceutical and medical device firms, as well as generic drug producers. Established in 2000, its main office is located in Chennai, India. TAKE Solutions Limited functions as a subsidiary of TAKE Solutions Pte. Limited.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Syngene International Ltd.
―
OneSource Specialty Pharma Limited
―